PD-L1 status and efficacy of immune check-point inhibitors (ICIs) in advanced cancer patients: A pooled analysis of randomized trials.

• DOI: 10.1200/jco.2020.38.15_suppl.e15263
• Publication Date: 2020-05-25T15:23:11Z
• Authors: Federica Biello; David James Pinato; Gloria Borra; Silvia Genestroni; Guido Siffredi; Ilaria Repetti; Veronica Martini; Feba mariam Varug...; Ajay Ram Vachanaram; Edoardo Mora; Simone Nardin; Paolo Bruzzi; Antonio Sica; Alessandra Gennari
• Keywords: Atezolizumab

e15263 Background: The introduction of immune check-point inhibitors (ICIs) in the treatment a broad range tumor types has led to significant and clinically meaningful improvement overall survival (OS) advanced disease stages. However, efficacy these agents is not consistent across trials routine practice. role PD-L1 expression as tumour-agnostic predictive correlate response ICIs remains unclear. We performed pooled analysis PD-1/PD-L1-targeted ICI regimens compared standard care (SoC) therapy according expression, based on landmark clinical studies. Methods: searched literature databases identify phase III randomized controlled that anti-PD-1/PD-L1 antibodies alone or combination with chemotherapy targeted against SoC different types. reported data, terms OS, status. Log hazard ratios (HRs) were studies by status inverse variance weighting. All statistical tests two-sided. Results: Twenty-four including 17687 randomised patients lung, renal, urothelial, liver, breast, head neck cancers melanoma, eligible for analysis. Efficacy immunohistochemical 1% cutoff ( < versus > 1%), was 11 (7126 patients). Overall, ICI-containing regimes significantly superior OS (pooled HR = 0.64; 95% CI 0.60 0.68). When data 0.66; 0.61 0.71 1%, 0.62; 0.56 0.68 >1% (p 0.7). Conclusions: favoring use over does seem be confined PD-L1-overexpressing tumours. difference appears be, at best, marginal.